Your browser is no longer supported. Please, upgrade your browser.
AMGN Amgen Inc. daily Stock Chart
Amgen Inc.
IndexS&P 500 P/E16.16 EPS (ttm)9.45 Insider Own0.20% Shs Outstand753.00M Perf Week1.74%
Market Cap115.00B Forward P/E12.56 EPS next Y12.16 Insider Trans-3.42% Shs Float750.34M Perf Month-5.96%
Income7.22B PEG2.03 EPS next Q2.75 Inst Own81.40% Short Float0.98% Perf Quarter4.50%
Sales22.16B P/S5.19 EPS this Y35.20% Inst Trans-0.69% Short Ratio2.27 Perf Half Y-3.20%
Book/sh38.09 P/B4.01 EPS next Y9.17% ROA10.00% Target Price182.35 Perf Year-1.70%
Cash/sh46.14 P/C3.31 EPS next 5Y7.96% ROE25.70% 52W Range127.70 - 177.64 Perf YTD-4.64%
Dividend4.00 P/FCF18.33 EPS past 5Y13.60% ROI12.50% 52W High-14.03% Beta0.85
Dividend %2.62% Quick Ratio4.70 Sales past 5Y7.60% Gross Margin81.00% 52W Low19.59% ATR2.86
Employees17900 Current Ratio5.00 Sales Q/Q9.80% Oper. Margin39.90% RSI (14)49.78 Volatility1.69% 1.89%
OptionableYes Debt/Eq1.20 EPS Q/Q18.50% Profit Margin32.60% Rel Volume0.79 Prev Close149.30
ShortableYes LT Debt/Eq1.12 EarningsApr 28 AMC Payout35.30% Avg Volume3.25M Price152.72
Recom2.50 SMA20-0.86% SMA50-0.48% SMA2000.54% Volume2,579,200 Change2.29%
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Jul-18-14Reiterated Deutsche Bank Buy $144 → $149
Apr-23-14Reiterated Oppenheimer Perform $121 → $122
May-25-16 08:20AM  Short Sellers Grow More Selective on Major Biotechs at 24/7 Wall St.
May-24-16 08:25AM  Billionaires Lightened Their Load on These 3 Widely-Held Stocks in Q1 at Motley Fool
May-23-16 12:25PM  Biotech: The Next Pricing Controversy? at
05:55AM  A Rudderless Market
May-21-16 11:06AM  Struggling Novartis heart drug boosted by new medical guidelines Reuters
May-20-16 06:05AM  AMGEN INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
May-19-16 06:24PM  Gambling debt, stock tip lead to $1 mln settlement but no charges for Mickelson Reuters
06:02PM  Amgen Announces Voting Results of Annual Meeting of Stockholders PR Newswire
04:34PM  Amgen Highlights Data To Be Presented At 21st Congress Of The European Hematology Association PR Newswire
12:52PM  Heart attack gene?
12:05PM  Can Amgens Prolia Continue Its Strong Growth Trajectory in 2016?
11:55AM  This Medical Breakthrough Could Drastically Reduce Heart Attacks at Fortune
May-18-16 05:14PM  [$$] Amgen Researchers Find Gene Associated With Lower Risk of Heart Disease at The Wall Street Journal
05:09PM  Amgen Researchers Find Gene That Reduces Heart Attack Risk at Forbes
05:06PM  Bayer to Showcase Latest Oncology Research at ASCO 2016 PR Newswire
05:05PM  Amgen Data To Be Presented At ASCO 2016 Demonstrates More Insights Into Treatment Options For Patients PR Newswire
05:00PM  Landmark deCODE genetics Study Points to a New Mechanism that Affects Cholesterol Levels and the Risk of Heart Disease PR Newswire
04:06PM  Inside Amgens Key Growth Drivers in 2016
02:06PM  Behind Amgens Plans to Penetrate the Migraine Segment
07:30AM  [$$] Venture Capitalists Bet on Vaccine Treatments for Cancer at The Wall Street Journal
May-17-16 04:06PM  AbbVies Biggest Drug Gets Patent Setback; Stock Tumbles
04:06PM  AbbVies Biggest Drug Gets Patent Setback; Stock Tumbles at Investor's Business Daily
04:00PM  Amgen's Breakaway from Cancer® Public Service Announcement Delivers Message That Education, Resources And Hope Are Essential In The Fight Against Cancer PR Newswire
11:26AM  Why AbbVie is Getting Hammered at
09:07AM  Understanding Amgens Guidance Update for 2016
May-16-16 08:07PM  How Competitive Pressures Could Impact Amgens Segmental Revenues in 2016
04:30PM  Regeneron's Spike Not Tied to Pfizer-Anacor Deal, But It Doesn't Hurt at TheStreet
04:30PM  Regeneron's Spike Not Tied to Pfizer-Anacor Deal, but It Doesn't Hurt at TheStreet
03:20PM  Glaxis Capital All-In on These Two Stocks After Slashing Portfolio at Insider Monkey
May-14-16 10:29AM  5 Dividend Stocks to Buy in May at Motley Fool
May-13-16 08:56AM  Short Sellers Dump Amgen And Baxalta Benzinga
08:09AM  Amgen, Inc. breached its 50 day moving average in a Bearish Manner : AMGN-US : May 13, 2016 at Capital Cube
08:04AM  Amgen Or Sanofi - Who is More Desperate for Medivation? Yahoo Finance Contributors
06:16AM  AMGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
May-12-16 09:14PM  Amgen Commences Exchange Offers for Certain Series of Outstanding Senior Notes from Exchange Eligible Holders PR Newswire
05:43PM  Bristol-Myers/AbbVie Empliciti Gets Approved in the EU Zacks
11:08AM  Which of Amgens Drugs Could Witness Muted Growth in 2016? Market Realist
09:08AM  Celgene Continues to Develop New Multiple Myeloma Drugs Market Realist
May-11-16 04:18PM  Another Major Insurer Is Tying Drug Prices to Health Outcomes at Fortune
01:17PM  Why Amgen Is Trading at a Discount Compared to Peers Market Realist
01:17PM  Understanding Amgens Analyst Recommendations in 2016 Market Realist
09:22AM  [$$] Health Insurers Push to Tie Drug Prices to Patient Results at The Wall Street Journal
08:54AM  Cignas new drug pricing plan targets expensive cholesterol drugs at MarketWatch
08:15AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
06:45AM  Hall of Fame Quarterback Joe Montana and Amgen Team Up to Launch Breakaway from Heart Disease to Make Heart Health a Priority PR Newswire
12:14AM  [$$] Health Insurers Push to Tie Drug Prices to Outcomes at The Wall Street Journal
May-10-16 04:50PM  Why Celgene Is Trading at a Premium Compared to Its Peers Market Realist
04:01PM  3 Things You Need to Know About Kite Pharma's First Quarter at Motley Fool
09:45AM  Kite Pharma (KITE) Posts Narrower-than-Expected Loss in Q1 Zacks
May-09-16 05:04PM  Keytruda: The Rising Hope of Merck & Co. Market Realist
09:15AM  Platelet BioGenesis Wins Amgen Golden Ticket For LabCentral PR Newswire
May-08-16 10:30PM  Charts See Possible Value in Apple, Facebook at TheStreet
May-06-16 05:00PM  Can The Top 10 S&P 500 Dividend Growers Continue Their Rapid Dividend Growth? at Insider Monkey
04:00PM  Amgen To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference PR Newswire
02:40PM  The Word on the Street: What Analysts Are Recommending for Gilead Sciences Now Market Realist
01:04PM  AMGEN INC Financials EDGAR Online Financials
10:41AM  Medivation: Better On Its Own? at
08:04AM  Medivation Takeover Talk: Sanofi May Lose Out Despite Offer To Raise Bid Yahoo Finance Contributors
May-05-16 07:01PM  Sanofi, Amgen Set to Get U.K. Access for Drugs With Discount at Bloomberg
07:01PM  Sanofi, Amgen cholesterol drugs win UK backing after price cuts Reuters
05:13PM  Charts are bullish for health care: Technician Yahoo Finance
04:48PM  Medivation: And Then There Were Five at
10:09AM  Regeneron Pharmaceuticals: The Eyleas Have It at
09:47AM  Amgen Said to Join Health-Care Pack Weighing Medivation Bids at Bloomberg
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Gilead, Celgene, Medivation and Biogen Zacks
09:08AM  How Much Upside Potential Does Alexion Have? Market Realist
May-04-16 02:04PM  Ioniss Metabolic Segment: Phase I and Phase II Studies Market Realist
01:16PM  Phase III Trial of Regorafenib in Patients with Unresectable Liver Cancer Meets Primary Endpoint of Improving Overall Survival PR Newswire
01:11PM  Biotech Stock Roundup: Amgen Impresses, Gilead Disappoints in Q1, Biogen to Spin Off Hemophilia Zacks
10:59AM  Kite (KITE) to Report Q1 Earnings: Will the Stock Disappoint? Zacks
10:17AM  Marten Transport Ltd (MRTN), Amgen Inc. (AMGN) and Parker-Hannifin Corp (PH) Witness Striking Insider Selling at Insider Monkey
May-03-16 08:30PM  As Google's secretive biotech spinoff ramps up, look who it's hiring at American City Business Journals
05:12PM  Regeneron Pharmaceuticals Inc Has a Lot to Prove on May 5 at Motley Fool
04:21PM  FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) PR Newswire
03:35PM  Emerging biotech company preps fall takeover of never-used Amgen space at American City Business Journals
03:04PM  Insulet Pumps Out 69% Revenue Growth in Q1, Reaffirms 2016 Guidance at Motley Fool
11:53AM  Medivation: Sanofi's Bid 'Significantly Undervaluing' Pipeline at
10:49AM  Biogen's Hemophilia Spin: Prelude to a Takeover? at
08:59AM  How to Trade 5 Biotech Stocks After a Fall -- Plus Jim Cramer's Take at TheStreet
May-02-16 04:52PM  AMGEN INC Files SEC form 10-Q, Quarterly Report EDGAR Online
03:47PM  Aside From 1 Eyesore, Amgen Delivers Another Solid Quarter at Motley Fool
03:22PM  Biotech ETFs Sink on Mixed Q1 Results Zacks
11:06AM  2 Dirt-Cheap Big Pharma Stocks Poised to Beat Biotech's Bad Rap at TheStreet
10:45AM  Amgen, Inc. :AMGN-US: Earnings Analysis: Q1, 2016 By the Numbers at Capital Cube
May-01-16 10:50AM  Analysts Make Major Changes to Top Biotech Ratings at 24/7 Wall St.
Apr-29-16 05:15PM  Top Trades: Biotech's brutal week CNBC
05:00PM  5 way to trade the mixed biotech sector CNBC
04:50PM  US stocks hit by health care woes but avoid bigger losses AP
01:56PM  A Typical Bad First Quarter For Biotech: Leerink at
01:14PM  What Are Analysts Saying About Q1 At Biotech's Big 4? Amgen, Biogen, Celgene, Gilead at Forbes
09:14AM  Amgen (AMGN) Tops Q1 Earnings & Revenues, Ups View Zacks
08:32AM  Pfizer Earnings Could Highlight Enbrel and Lyrica Sales Decline Yahoo Finance Contributors
08:00AM  Early movers: AMZN, VRX, TIVO, TYC, DAL, VFC, MCO, NWL, BUD & more at CNBC
01:51AM  Edited Transcript of AMGN earnings conference call or presentation 28-Apr-16 9:30pm GMT Thomson Reuters StreetEvents
Apr-28-16 08:16PM  Amgen posts 1Q sales, profit jumps, raises profit forecasts AP
07:20PM  Amgen profit sails past Street expectations; raises 2016 outlook Reuters
05:59PM  Q1 Earnings Reports Continue the Deluge: AMZN, GILD, AMGN Zacks
05:46PM  [$$] Amgen Profit Rises 17%, Guidance Raised at The Wall Street Journal
05:41PM  Amgen (AMGN) Beats Q1 Earnings Estimates, Raises 2016 Outlook Zacks
05:37PM  After Hours: Amazon, LinkedIn, Baidu, Expedia Soar, Gilead Flops at Investor's Business Daily
Amgen Inc., a biotechnology company, engages in discovering, developing, manufacturing, and delivering human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its principal products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of high cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc.; UCB; Novartis AG; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Balachandran MadhavanEVP, OperationsMay 04Sale154.1230,0004,623,62455,996May 05 08:16 PM
BALTIMORE DAVIDDirectorApr 29Sale157.213,312520,68432,350May 03 07:12 PM
BALTIMORE DAVIDDirectorMar 30Option Exercise50.445,000252,20037,350Mar 31 06:01 PM
HERRINGER FRANK CDirectorMar 14Option Exercise50.445,000252,20030,608Mar 16 06:48 PM
COFFMAN VANCE DDirectorMar 09Option Exercise50.445,000252,20043,447Mar 10 06:55 PM
Bradway Robert AChairman, CEO and PresidentMar 02Option Exercise50.4484,0004,236,960447,102Mar 04 06:07 PM
Bradway Robert AChairman, CEO and PresidentMar 02Sale146.4820,0002,929,566383,102Mar 04 06:07 PM
de Carbonnel FrancoisDirectorAug 31Sale153.845,000769,19215,150Sep 02 07:46 PM
Hassan FredDirectorAug 19Buy166.633,010501,5623,582Aug 20 05:58 PM
PELHAM JUDITH CDirectorJul 31Sale180.405,035908,31411,890Aug 04 06:31 PM
Patton Cynthia MSVP & CCOJun 02Sale157.064,530711,48216,571Jun 03 07:16 PM